Market Overview:
The global ganciclovir market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of CMV infections, rising demand for ganciclovir in AIDS and tube transplant applications, and growing awareness about the benefits of ganciclovir therapy. However, factors such as high cost of treatment and lack of reimbursement policies are likely to restrain the growth of this market during the forecast period. Based on type, the global ganciclovir market can be segmented into injection and oral segments. The injection segment is expected to account for a larger share than the oral segment in terms of revenue during 2018-2030 owing to its higher adoption rates across regions. By application, AIDS is estimated to account for a major share in terms of revenue in 2018 followed by tube transplantation and malignant neoplasms applications respectively.
Product Definition:
Ganciclovir is a synthetic nucleoside analogue with antiviral activity. It is used to treat cytomegalovirus (CMV) retinitis in people with AIDS and to prevent CMV disease in transplant recipients.
Injection:
Injection is a form of chemotherapy used to treat cancer. Chemotherapy is usually given together with radiotherapy and surgery. In most cases, it's used for treating cancer that has spread to other parts of the body after surgery or treatment with radiation therapy has failed. The medicine works by killing the cancer cells and helps stop their growth.
Oral:
Oral Ganciclovir is an antiviral drug used for the treatment of chronic viral diseases such as cytomegalovirus, myelitis, and oral mucositis. It is also used in the treatment of acute ganciclovine toxicity. The drug was approved by FDA in 1995 for treating these conditions and has been widely prescribed ever since due to its ease of administration.
Application Insights:
The application segment is sub-divided into AIDS, CMV infection, tube transplantation, and other applications. In 2017, the AIDS segment dominated the global market with a revenue share of over 90%. The high prevalence of HIV/AIDS has resulted in an increased demand for ganciclovir.
Infection with cytomegalovirus (CMV) results in damage to the kidneys and liver which eventually leads to death of the infected cell. CMV infection also causes vision loss which encourages its usage as a therapeutic tool against retinitis pigmentosa and cataract formation. This factor encourages usage of ganciclovir againstCMV infections in humans leading to an increase in demand across various regions such as North America & Europe.
Regional Analysis:
North America dominated the global ganciclovir market in 2017. The presence of a large number of manufacturers coupled with high R&D investment by companies operating within this region is expected to be the major factor responsible for its largest share. In addition, increasing incidence rates of COVID-19 positive cases are also anticipated to contribute towards larger revenue generation from North America over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to factors such as improving healthcare infrastructure and growing patient awareness levels regarding available treatment options in emerging countries like China and India.
Growth Factors:
- Increasing incidence of cytomegalovirus (CMV) infections: CMV is a common virus that can cause serious health problems in people with weakened immune systems. The number of people infected with CMV is increasing due to the aging population and the increasing use of immunosuppressive therapies. This is expected to drive the growth of the ganciclovir market.
- Growing demand for ganciclovir in emerging markets: The demand for ganciclovir is growing rapidly in emerging markets, such as China and India, due to the rising incidence of CMV infections and increasing awareness about its benefits. This is expected to drive the growth of the global ganciclovir market.
- Development of new formulations and delivery methods: Pharmaceutical companies are developing new formulations and delivery methods for ganciclovir, which are expected to improve its efficacy and safety profile. This is likely to boost demand for this drug, leading to higher market growth rates over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Ganciclovir Market Research Report
By Type
Injection, Oral
By Application
AIDS, Tube transplant, Malignant neoplasms, CMV Infection
By Companies
Roche, Bausch & Lomb, Fresenius Kabi, Luitpold, Huatai Pharmaceutical, Wuhan Hualong Bio-pharmaceutical, Luoxin, HUBEI KEYI, Tungshun Group, Tiantianming
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Ganciclovir Market Report Segments:
The global Ganciclovir market is segmented on the basis of:
Types
Injection, Oral
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
AIDS, Tube transplant, Malignant neoplasms, CMV Infection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Bausch & Lomb
- Fresenius Kabi
- Luitpold
- Huatai Pharmaceutical
- Wuhan Hualong Bio-pharmaceutical
- Luoxin
- HUBEI KEYI
- Tungshun Group
- Tiantianming
Highlights of The Ganciclovir Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Oral
- By Application:
- AIDS
- Tube transplant
- Malignant neoplasms
- CMV Infection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ganciclovir Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ganciclovir is an antiviral medication used to treat herpes simplex virus (HSV) infections. It is also used to prevent HSV infections in people who are at high risk for them, such as those with HIV/AIDS or cancer. Ganciclovir can be taken by mouth, injection into a muscle, or as a cream applied topically.
Some of the major companies in the ganciclovir market are Roche, Bausch & Lomb, Fresenius Kabi, Luitpold, Huatai Pharmaceutical, Wuhan Hualong Bio-pharmaceutical, Luoxin, HUBEI KEYI, Tungshun Group, Tiantianming.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ganciclovir Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ganciclovir Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ganciclovir Market - Supply Chain
4.5. Global Ganciclovir Market Forecast
4.5.1. Ganciclovir Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ganciclovir Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ganciclovir Market Absolute $ Opportunity
5. Global Ganciclovir Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ganciclovir Market Size and Volume Forecast by Type
5.3.1. Injection
5.3.2. Oral
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ganciclovir Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ganciclovir Market Size and Volume Forecast by Application
6.3.1. AIDS
6.3.2. Tube transplant
6.3.3. Malignant neoplasms
6.3.4. CMV Infection
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ganciclovir Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ganciclovir Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ganciclovir Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ganciclovir Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ganciclovir Demand Share Forecast, 2019-2026
9. North America Ganciclovir Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ganciclovir Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ganciclovir Market Size and Volume Forecast by Application
9.4.1. AIDS
9.4.2. Tube transplant
9.4.3. Malignant neoplasms
9.4.4. CMV Infection
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ganciclovir Market Size and Volume Forecast by Type
9.7.1. Injection
9.7.2. Oral
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ganciclovir Demand Share Forecast, 2019-2026
10. Latin America Ganciclovir Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ganciclovir Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ganciclovir Market Size and Volume Forecast by Application
10.4.1. AIDS
10.4.2. Tube transplant
10.4.3. Malignant neoplasms
10.4.4. CMV Infection
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ganciclovir Market Size and Volume Forecast by Type
10.7.1. Injection
10.7.2. Oral
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ganciclovir Demand Share Forecast, 2019-2026
11. Europe Ganciclovir Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ganciclovir Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ganciclovir Market Size and Volume Forecast by Application
11.4.1. AIDS
11.4.2. Tube transplant
11.4.3. Malignant neoplasms
11.4.4. CMV Infection
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ganciclovir Market Size and Volume Forecast by Type
11.7.1. Injection
11.7.2. Oral
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. ByCountry
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ganciclovir Demand Share, 2019-2026
12. Asia Pacific Ganciclovir Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ganciclovir Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ganciclovir Market Size and Volume Forecast by Application
12.4.1. AIDS
12.4.2. Tube transplant
12.4.3. Malignant neoplasms
12.4.4. CMV Infection
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ganciclovir Market Size and Volume Forecast by Type
12.7.1. Injection
12.7.2. Oral
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ganciclovir Demand Share, 2019-2026
13. Middle East & Africa Ganciclovir Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ganciclovir Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ganciclovir Market Size and Volume Forecast by Application
13.4.1. AIDS
13.4.2. Tube transplant
13.4.3. Malignant neoplasms
13.4.4. CMV Infection
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ganciclovir Market Size and Volume Forecast by Type
13.7.1. Injection
13.7.2. Oral
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ganciclovir Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Ganciclovir Market: Market Share Analysis
14.2. Ganciclovir Distributors and Customers
14.3. Ganciclovir Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bausch & Lomb
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Fresenius Kabi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Luitpold
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Huatai Pharmaceutical
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Wuhan Hualong Bio-pharmaceutical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Luoxin
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. HUBEI KEYI
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Tungshun Group
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Tiantianming
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
